Literature DB >> 16698625

Recurrent stillbirths: a matched case-control study of unexplained stillbirths at term.

J L Onwude1, V Eisman, D O Selo-Ojeme.   

Abstract

The aim of this study was to assess the recurrent risk of an unexplained stillbirth at term. A total of 75 women who delivered stillbirths were matched for maternal age and parity with 75 controls. After excluding explained stillbirths, matched cases and controls were compared for maternal age, length of gestation, birth weight and 'interval to next birth'. The main outcome measure was the frequency of recurrence of a stillbirth. Both groups were similar for maternal age and length of gestation. Birth weight was marginally different (odds ratio (OR) = 0.997, 95% confidence interval (CI) 0.996, 0.999) and 'interval to next birth' was longer (OR = 1.08, 95% CI 1.00, 1.17). There were no stillbirths in cases and controls at follow-up. We conclude that a woman who has had an unexplained stillbirth at term has no greater risk of recurrence than a matched control. However, the 'interval to next birth' was significantly longer.

Entities:  

Mesh:

Year:  2006        PMID: 16698625     DOI: 10.1080/01443610500508303

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  3 in total

1.  Aetiological Classification of Stillbirths: A Case Control Study.

Authors:  Sonal A Kumbhare; Nandita K Maitra
Journal:  J Obstet Gynaecol India       Date:  2015-06-14

2.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

3.  Adverse Perinatal Outcome in Subsequent Pregnancy after Stillbirth by Placental Vascular Disorders.

Authors:  Francesca Monari; Giulia Pedrielli; Patrizia Vergani; Elisa Pozzi; Federico Mecacci; Caterina Serena; Isabella Neri; Fabio Facchinetti
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.